|
Index of reports
> Cases with Diarrhoea (71)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include diarrhoea. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 71 Next >>
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-22
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate Sodium
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin
Possible Vincristine side effects in male
Reported by a physician from India on 2012-08-17
Patient: male, weighing 65.0 kg (143.0 pounds)
Reactions: Diarrhoea, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Blinded Gp2013
Dosage: code not broken
Indication: non-Hodgkin's Lymphoma
Start date: 2012-08-06
Blinded Mabthera
Dosage: code not broken
Indication: non-Hodgkin's Lymphoma
Start date: 2012-08-06
Blinded NO Treatment Received
Dosage: code not broken
Indication: non-Hodgkin's Lymphoma
Start date: 2012-08-06
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-14
Patient:
Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-08-10
Patient:
Reactions: Diarrhoea, Anaemia, Dizziness, Pulmonary Mycosis, Lethargy
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-04
Doxorubicin HCL
Dosage: 100 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-04
Prednisolone
Dosage: 100 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-08
Rituximab
Dosage: 750 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-04
Velcade
Dosage: 2.6 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-04
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-04-03
End date: 2012-07-04
Other drugs received by patient: Prednisolone; Tramadol HCL; Chlorhexidine Gluconate; Omeprazole; Itraconazole; Acyclovir; Symbicort; Montelukast; Cetraben / 01561901 /; Fluconazole; Nitrofurantoin; Citalopram Hydrobromide; NEO-Mercazole TAB; Cotrim; Ferrous Fumarate; Ventolin; Enoxaparin Sodium; Metoclopramide
Possible Vincristine side effects in 46 year old female
Reported by a individual with unspecified qualification from United States on 2012-08-08
Patient: 46 year old female
Reactions: Dyspnoea, Pain in Extremity, Myelodysplastic Syndrome, General Physical Health Deterioration, Pyrexia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Skin Discolouration, Central Nervous System Infection, Small Intestinal Haemorrhage, Cough
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Indication: Diffuse Large B-Cell Lymphoma
Carmustine
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 400 ug, intravenous, every two months
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Idarubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Melphalan (Melphalan) (Melphalen)
Indication: Diffuse Large B-Cell Lymphoma
Melphalan Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Rituximab (Rituximab) (Rituximab)
Indication: Diffuse Large B-Cell Lymphoma
Rituximab (Rituximab) (Rituximab)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 41 year old male
Reported by a physician from Canada on 2012-08-03
Patient: 41 year old male
Reactions: Ecthyma, Diarrhoea, Pseudomonas Infection, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma Stage IV
Doxorubicin HCL
Indication: B-Cell Lymphoma Stage IV
Prednisone
Indication: B-Cell Lymphoma Stage IV
Rituximab
Indication: B-Cell Lymphoma Stage IV
Vincristine
Indication: B-Cell Lymphoma Stage IV
Other drugs received by patient: Epogen; Enoxaparin Sodium; Filgrastim
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Vincristine side effects in 17 year old female
Reported by a physician from United States on 2012-07-25
Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)
Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Sinus Tachycardia, Spinal Cord Oedema, Peripheral Motor Neuropathy, Epistaxis, Neuralgia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Cytarabine
Dosage: 75mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Dalteparin Sodium
Indication: Product Used FOR Unknown Indication
Mercaptopurine
Dosage: 60mgm2 cyclic
Administration route: Oral
Indication: T-Cell Type Acute Leukaemia
Methotrexate
Indication: T-Cell Type Acute Leukaemia
Nelarabine
Dosage: 650mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2012-04-13
PEG-Asparaginase
Indication: T-Cell Type Acute Leukaemia
Vincristine
Dosage: 1.5mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Other drugs received by patient: Insulin Aspart; Lansoprazole; Vancomycin; Nystatin; Piperacillin and Tazobactam; Voriconazole
Possible Vincristine side effects in 17 year old male
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-07-23
Patient: 17 year old male
Reactions: Abdominal Pain, Rhabdomyolysis, Pain in Extremity, Disseminated Intravascular Coagulation, Chromaturia, Pancytopenia, Pyrexia, Renal Failure, Renal Impairment, Diarrhoea, Clostridial Infection, Septic Shock
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cefepime
Indication: Pyrexia
Doxorubicin HCL
Indication: Ewing's Sarcoma Metastatic
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Netilmicin Sulfate
Indication: Pyrexia
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in 17 year old female
Reported by a physician from United States on 2012-07-13
Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)
Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Spinal Cord Oedema, Peripheral Motor Neuropathy, Sinus Tachycardia, Neuralgia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Cytarabine
Dosage: 75mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Dalteparin Sodium
Indication: Product Used FOR Unknown Indication
Mercaptopurine
Dosage: 60mgm2 cyclic
Administration route: Oral
Indication: T-Cell Type Acute Leukaemia
Methotrexate
Indication: T-Cell Type Acute Leukaemia
Nelarabine
Dosage: 650mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2012-04-13
PEG-Asparaginase
Indication: T-Cell Type Acute Leukaemia
Vincristine
Dosage: 1.5mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Other drugs received by patient: Insulin Aspart; Nystatin; Voriconazole; Vancomycin; Piperacillin and Tazobactam; Lansoprazole
Possible Vincristine side effects in male
Reported by a physician from Germany on 2012-07-12
Patient: male
Reactions: Stomatitis, Diarrhoea, Dehydration, Pain of Skin, Palmar-Plantar Erythrodysaesthesia Syndrome, Gastrointestinal Inflammation
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1640 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Doxorubicin HCL
Dosage: 110 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-20
Prednisone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Rituximab
Dosage: 800 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-16
Vincristine
Dosage: 2 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Amiodarone Hydrochloride; Levothyroxine Sodium; Digitoxin TAB
Possible Vincristine side effects in 17 year old female
Reported by a physician from United States on 2012-07-09
Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)
Reactions: Blood Bilirubin Increased, Dysphagia, Cerebrovascular Accident, Caecitis, Eating Disorder, Dysphonia, Diarrhoea, Acute Respiratory Distress Syndrome, Depressed Level of Consciousness, Peripheral Motor Neuropathy, Sinus Tachycardia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Cytarabine
Dosage: 75mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Dalteparin Sodium
Indication: Product Used FOR Unknown Indication
Mercaptopurine
Dosage: 60mgm2 cyclic
Administration route: Oral
Indication: T-Cell Type Acute Leukaemia
Methotrexate
Indication: T-Cell Type Acute Leukaemia
Nelarabine
Dosage: 650mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2012-04-13
PEG-Asparaginase
Indication: T-Cell Type Acute Leukaemia
Vincristine
Dosage: 1.5mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Other drugs received by patient: Lansoprazole; Piperacillin and Tazobactam; Vancomycin; Voriconazole; Insulin Aspart; Nystatin
Possible Vincristine side effects in male
Reported by a physician from Germany on 2012-07-09
Patient: male
Reactions: Stomatitis, Diarrhoea, Pain of Skin, Dehydration, Gastrointestinal Inflammation, Palmar-Plantar Erythrodysaesthesia Syndrome
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Cyclophosphamide
Dosage: reduced dose
Start date: 2012-06-05
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Doxorubicin Hydrochloride
Dosage: reduced dose
Start date: 2012-06-05
Mabthera
Dosage: reduced dose
Start date: 2012-06-05
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-16
Pegfilgrastim
Indication: B-Cell Lymphoma
Start date: 2012-04-20
Prednisone TAB
Dosage: reduced dose
Start date: 2012-06-05
Prednisone TAB
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-17
Vincristine
Dosage: reduced dose
Start date: 2012-06-05
Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Levothyroxine Sodium; Digitoxin TAB; Amiodarone HCL
Possible Vincristine side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium
Possible Vincristine side effects in
Reported by a physician from United States on 2012-06-28
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Rituximab
Dosage: on day 8 from cycle 3 to 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26
Patient:
Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: given on day 1 of each cycle
Indication: B-Cell Lymphoma
Mabthera
Dosage: on day 1 of every cycle
Indication: B-Cell Lymphoma
Prednisolone
Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
Administration route: Oral
Indication: B-Cell Lymphoma
Vincristine
Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-25
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Stomatitis, Vomiting, Dyspnoea, Nausea, Gastrointestinal Toxicity, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5 of cycle 2,4 and 6
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient:
Reactions: Urticaria, Pyrexia, Headache, Oropharyngeal Pain, Constipation, Polyneuropathy, Fatigue, Dyspepsia, Oedema Peripheral, Cough, Dyspnoea, Vomiting, Nausea, Rash, Dysgeusia, Diarrhoea, Alopecia, Neutropenia, Respiratory Tract Infection, Leukopenia, Infection, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Ofatumumab
Indication: B-Cell Lymphoma
Ofatumumab
Prednisone TAB
Administration route: Oral
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Other drugs received by patient: Acetaminophen; Cetirizine; Glucocorticoids
Possible Vincristine side effects in 17 year old female
Reported by a physician from United States on 2012-06-08
Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)
Reactions: Blood Bilirubin Increased, Pyrexia, Caecitis, Loss of Consciousness, Oedema Peripheral, Pulmonary Oedema, Hypocalcaemia, Acute Respiratory Distress Syndrome, Melaena, Hypertriglyceridaemia, Epistaxis, Dysphagia, Anaemia, Hyperglycaemia, General Physical Health Deterioration, Eating Disorder, Tremor, Cerebral Infarction, Depressed Level of Consciousness, Neutropenia, Confusional State, Dyskinesia, Somnolence, Splenic Infarction, Hypokalaemia, Pleural Effusion, White Blood Cell Count Decreased, Cerebrovascular Accident, Ascites, Diarrhoea, Hypophagia, Hypoalbuminaemia, Sinus Tachycardia, Hypertension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Cytarabine
Dosage: 75mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Dalteparin Sodium
Indication: Product Used FOR Unknown Indication
Mercaptopurine
Dosage: 60mgm2 cyclic
Administration route: Oral
Indication: T-Cell Type Acute Leukaemia
Methotrexate
Indication: T-Cell Type Acute Leukaemia
Nelarabine
Dosage: 650mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2012-04-13
Oncaspar
Indication: T-Cell Type Acute Leukaemia
Vincristine
Dosage: 1.5mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Other drugs received by patient: Nystatin; Lansoprazole; Insulin Aspart; Piperacillin and Tazobactam; Vancomycin; Voriconazole
Possible Vincristine side effects in 60 year old female
Reported by a physician from United States on 2012-06-05
Patient: 60 year old female
Reactions: Diarrhoea, Dehydration, Colitis, Hypokalaemia, Hyperuricaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-11-17
Sprycel
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-11-17
Vincristine
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-11-17
Possible Vincristine side effects in 17 year old female
Reported by a physician from United States on 2012-05-31
Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)
Reactions: Blood Bilirubin Increased, Cerebrovascular Accident, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Sinus Tachycardia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Cytarabine
Dosage: 75mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Dalteparin Sodium
Indication: Product Used FOR Unknown Indication
Mercaptopurine
Dosage: 60mgm2 cyclic
Administration route: Oral
Indication: T-Cell Type Acute Leukaemia
Methotrexate
Indication: T-Cell Type Acute Leukaemia
Nelarabine
Dosage: 650mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Start date: 2012-04-13
PEG-Asparaginase
Indication: T-Cell Type Acute Leukaemia
Vincristine
Dosage: 1.5mgm2 cyclic
Indication: T-Cell Type Acute Leukaemia
Other drugs received by patient: Voriconazole; Insulin Aspart; Nystatin; Vancomycin; Lansoprazole; Piperacillin and Tazobactam
Possible Vincristine side effects in 77 year old male
Reported by a physician from Denmark on 2012-05-29
Patient: 77 year old male, weighing 97.0 kg (213.4 pounds)
Reactions: Fatigue, Malaise, Diarrhoea, Anaemia, Dizziness, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1612 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Doxorubicin HCL
Dosage: 107 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Neulasta
Dosage: 6 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-26
Prednisolone
Dosage: 100 mg, unk
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Rituximab
Dosage: 750 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Other drugs received by patient: Pinex; Sulphamethizole; Valacyclovir Hydrochloride; Omeprazole
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18
Patient:
Reactions: Urticaria, Headache, Pyrexia, Oropharyngeal Pain, Constipation, Polyneuropathy, Fatigue, Dyspepsia, Oedema Peripheral, Cough, Dyspnoea, Vomiting, Nausea, Rash, Dysgeusia, Diarrhoea, Alopecia, Neutropenia, Respiratory Tract Infection, Leukopenia, Infection, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Ofatumumab
Indication: B-Cell Lymphoma
Ofatumumab
Prednisone
Administration route: Oral
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Other drugs received by patient: Cetirizine; Acetaminophen; Glucocorticoids
Possible Vincristine side effects in 1 year old male
Reported by a physician from United States on 2012-05-14
Patient: 1 year old male, weighing 8.8 kg (19.4 pounds)
Reactions: Food Intolerance, Parainfluenzae Virus Infection, Vomiting, Lung Infection, Cytomegalovirus Viraemia, Cytomegalovirus Colitis, Pneumonia Cytomegaloviral, Respiratory Syncytial Virus Infection, Pneumocystis Jiroveci Pneumonia, Lower Respiratory Tract Infection Viral, Diarrhoea
Adverse event resulted in: death
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-09-30
Lestaurtinib
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-09-30
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-09-30
Vincristine
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-09-30
Possible Vincristine side effects in male
Reported by a physician from Denmark on 2012-05-11
Patient: male, weighing 97.0 kg (213.4 pounds)
Reactions: Viral Infection, Body Temperature Increased, Anaemia, Febrile Neutropenia, Pallor, Fatigue, Malaise, Dyspnoea Exertional, Diarrhoea, Dizziness
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Cyclophosphamide
Start date: 2011-04-26
End date: 2011-04-26
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-04-26
End date: 2011-04-26
Doxorubicin Hydrochloride
Start date: 2011-03-25
Vincristine
Start date: 2011-04-26
End date: 2011-04-26
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Other drugs received by patient: Valacyclovir Hydrochloride; Rituximab; Prednisolone; Prednisolone; Rituximab; Pinex Junior; Neulasta; Omeprazole; Sulphamethizole; Neulasta; Prednisolone
Possible Vincristine side effects in female
Reported by a individual with unspecified qualification from Denmark on 2012-05-11
Patient: female, weighing 97.0 kg (213.4 pounds)
Reactions: Viral Infection, Malaise, Diarrhoea, Anaemia, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1612 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Cyclophosphamide
Dosage: 1612 mg, unk
Start date: 2011-04-26
End date: 2011-04-26
Cyclophosphamide
Dosage: dosage form: unspecified
Start date: 2011-04-26
End date: 2011-04-26
Cyclophosphamide
Dosage: dosage form: unspecified
Start date: 2011-03-25
Doxorubicin HCL
Dosage: 107 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Doxorubicin HCL
Dosage: 107 mg, unk
Start date: 2011-04-26
End date: 2011-04-26
Vincristine
Dosage: dosage form: unspecified
Start date: 2011-03-25
Vincristine
Dosage: dosage form: unspecified
Start date: 2011-04-26
End date: 2011-04-26
Vincristine
Dosage: 2 mg, unk
Start date: 2011-04-26
End date: 2011-04-26
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Other drugs received by patient: Prednisone TAB; Neulasta; Omeprazole; Prednisolone; Prednisolone; Sulphamethizole; Rituximab; Prednisone TAB; Neulasta; Valaciclovir; Pinex; Prednisolone; Rituximab
Possible Vincristine side effects in 1 year old female
Reported by a physician from United States on 2012-05-10
Patient: 1 year old female, weighing 7.6 kg (16.8 pounds)
Reactions: Dyspnoea, Vomiting, Hypothermia, Nausea, Chills, Pyrexia, Peripheral Sensory Neuropathy, Sinus Bradycardia, Hypokalaemia, Diarrhoea, Ileus, Hypoalbuminaemia, Lung Infiltration, Candidiasis, Influenza Like Illness
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: unk mg, cyclic
Indication: B Precursor Type Acute Leukaemia
End date: 2012-03-22
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-23
End date: 2012-03-23
Prednisone TAB
Dosage: 20 mg/m2, unk
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-23
End date: 2012-03-24
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-23
End date: 2012-03-23
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-23
End date: 2012-03-23
Possible Vincristine side effects in 77 year old male
Reported by a physician from Denmark on 2012-04-26
Patient: 77 year old male, weighing 97.0 kg (213.4 pounds)
Reactions: Fatigue, Malaise, Diarrhoea, Anaemia, Dizziness, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1612 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Doxorubicin HCL
Dosage: 107 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Neulasta
Dosage: 6 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-26
Prednisolone
Dosage: 100 mg, unk
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Rituximab
Dosage: 750 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-03-25
Other drugs received by patient: Sulphamethizole; Omeprazole; Pinex; Valacyclovir Hydrochloride
Page 1 Next >>
|
